Delivery Order SPE2DB24D2010-SPE2DB25FABDL
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $1,290.75 on September 10, 2025, for the supply of Myrbetriq ER 25 mg tablets (90-count). This is a firm fixed price, non-set-aside contract with a completion date of September 11, 2025, and performance occurring at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a $25,044.82 delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Myrbetriq ER 50 mg tablets (90-count units). This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (contract SPE2DX), valued at $999,999,999.00 through December 2026. The place of performance is AmerisourceBergen's corporate headquarters...
- The Defense Logistics Agency awarded a $7,794.93 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Myrbetriq ER 50 mg tablets (90-count unit). The contract utilizes firm fixed-price pricing with an ultimate completion date of July 29, 2025, and represents a non-competitive, non-set-aside award. This delivery order is executed under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $1...
- The Defense Logistics Agency awarded a $9,784.94 delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Myrbetriq ER 25 mg tablets (90-count units). This firm fixed-price contract represents a child order under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion comprehensive pharmaceutical supply vehicle running through December 2026. The contract was competitively awarded with no set-aside...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a Delivery Order valued at $9,586.26 by the Defense Logistics Agency (DLA) on August 12, 2025, for the supply of Myrbetriq ER 25 mg tablets (90-count). This competitively awarded, firm fixed-price contract carries an ultimate completion date of August 13, 2025, and represents a non-set-aside procurement. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp for $28,074.21 on September 10, 2025, for the supply of Myrbetriq ER 50 mg tablets (90-count supply). This is a firm fixed-price, non-set-aside delivery order with an ultimate completion date of September 11, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical procurement...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Myrbetriq ER 25 mg tablets (90-count units) with a ceiling value of $33,370.13. This firm fixed-price delivery order, which is not set-aside and competitively awarded, is performed at the contractor's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 19, 2025. The contract represents a continuation of AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $1,923.12 to AmerisourceBergen Drug Corp for Myrbetriq ER 25 mg tablets (90-count supply) on July 28, 2025, with an ultimate completion date of July 29, 2025. This is a firm fixed price contract with no set-aside designation, competitively awarded through open competition. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Myrbetriq ER 25 mg tablets (90-count units) valued at $10,076.28. This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement and is scheduled for completion by August 13, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, fulfilled this order through its corporate office...
- The Defense Logistics Agency awarded a delivery order valued at $25,697.77 to AmerisourceBergen Drug Corp for the supply of Myrbetriq ER 50 mg tablets (90-count units) under a firm fixed-price contract. The award was made on August 29, 2025, with an ultimate completion date of September 2, 2025, and represents a non-set-aside competitive award. Performance will take place at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- SPE2DB24D2010Indefinite Delivery Contract
- SPE2DB24D2010-SPE2DB25FABDLDelivery Order
The Defense Logistics Agency awarded a $54,339.92 delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Myrbetriq ER 25 mg tablets (90-count units). This is a firm fixed-price, non-set-aside contract with a completion date of September 11, 2025, and performance to be executed from the contractor's facility in Conshohocken, Pennsylvania. The award represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a comprehensive $999.99 billion global pharmaceutical support vehicle designated as SPE2DX and running through December 2026. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical federal healthcare vendor that supplies a broad range of medications and medical commodities to military and veteran healthcare systems. The company's extensive portfolio of federal contracts with the Defense Logistics Agency demonstrates its capability to meet competitive procurement requirements across multiple therapeutic domains, including specialty medications, brand-name and generic pharmaceuticals, vaccines, and medical devices. This delivery order for Myrbetriq, a urological treatment medication, exemplifies the company's role in supporting the Defense Health Agency and other federal healthcare systems through the DLA's pharmaceutical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $54.3k | 9/10/25 |